Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 15/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4796083 | 0.95 | ESR1 (0.53) | ESR1ESR2CYP19A1KMT2A | |
| SCHEMBL4667966 | 0.92 | ESR1 (0.69) | ESR1ESR2CYP19A1 | |
| SCHEMBL4667995 | 0.88 | ESR1 (0.62) | ESR1ESR2CYP19A1 | |
| SCHEMBL4665843 | 0.88 | ESR1 (0.53) | ESR1ESR2CYP19A1KMT2A | |
| SCHEMBL3810879 | 0.87 | ESR1 (0.67) | ESR1ESR2CYP19A1 | |
| SCHEMBL4666272 | 0.86 | ESR1 (0.57) | ESR1ESR2CYP19A1 | |
| SCHEMBL4665856 | 0.85 | CYP19A1 (0.60) | ESR1ESR2CYP19A1 | |
| SCHEMBL4665812 | 0.84 | ESR1 (0.60) | ESR1ESR2CYP19A1 | |
| SCHEMBL4638954 | 0.82 | ESR1 (0.73) | ESR1ESR2KMT2A | |
| SCHEMBL4667638 | 0.82 | ESR1 (0.51) | ESR1ESR2CYP19A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951216-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | claimed |
| WO-2007062145-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | claimed |
| US-20080255078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-10-16 | — | — | US | disclosed |
| US-20080255078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-10-16 | — | — | US | disclosed |
| US-20080255078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-10-16 | — | — | US | disclosed |
| EP-1951216-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062145-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | ESR1 4/4885ESR2 2/4885CYP19A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.